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Influenza is a viral infection that affects much of the global population each year. Vaccination remains the
most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used
since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Institute of
Experimental Medicine (IEM), Saint Petersburg, Russia, have been successfully used in Russia since 1987.
In 2006, the World Health Organization (WHO) announced a Global action plan for influenza vaccines
(GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a pan-
demic situation, included LAIV in the GAP.
BioDiem Ltd., a vaccine development company based in Melbourne, Australia which held the rights for
the Russian LAIV, licensed this technology to WHO in 2009. WHO was permitted to grant sub-licenses to
vaccine manufacturers in newly industrialized and developing countries to use the Russian LAIV for the
development, manufacture, use and sale of pandemic and seasonal LAIVs. To date, WHO has granted sub-
licenses to vaccine manufacturers in China (Changchun BCHT Biotechnology Co., Ltd.), India (Serum
Institute of India Pvt. Ltd.) and Thailand (Government Pharmaceutical Organization). In parallel, in
2009, IEM signed an agreement with WHO, under which IEM committed to supply pandemic and sea-
sonal candidate vaccine viruses to the sub-licensees.
This paper describes the progress made by collaborators from China, India, Russia and Thailand in
developing preventive measures, including LAIV against pandemic influenza.
 2016 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Influenza is a life-threatening viral infection that may affect up
to 40% of the world’s population each year [1]. Vaccination remains
the most effective means of preventing seasonal influenza epi-
demics, which are associated with significant morbidity and mor-
tality worldwide.
Long-term observations have shown that live attenuated influ-
enza vaccine (LAIV) has some major advantages over inactivated
influenza vaccine (IIV). These advantages include ease of needle-
free delivery, extremely low rate of adverse reactions, smaller
infrastructure requirement for manufacturing, limited down-
stream processing and significantly higher yield in eggs (nearly
15 doses of LAIV can be produced from one embryonated egg).
These factors make LAIV especially attractive for developingcountries with a large population. Furthermore, the concept of
replicating the vaccine virus in the nasal cavity and thus generating
a specific immune response at the site of infection appears to be
the most appropriate mode of immunization.
All these features of LAIV become even more relevant with the
emergence of potentially pandemic influenza viruses of different
serotypes. The World Health Organization (WHO) recognized the
advantages of LAIV over IIV in the event of a pandemic and therefore
included LAIV in its Global action plan for influenza vaccines [2,3].
In Russia, LAIV has a long history of development, stage-wise
improvement, licensing and use in public health. Since 1987,
Russian LAIV has been used for the prophylaxis of influenza in
children aged over three years, in adults and in the elderly.
Currently, reassortant viruses for Russian LAIV are prepared by
classical reassortment in eggs ofwild-type influenza A and B viruses
with two cold-adaptedmaster donor viruses (MDVs) as a backbone:
A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69, respectively.
Russian LAIV has been shown through studies to consistently
provide superior effective protection, especially in children,
compared to IIV.
Table 1
List of seasonal LAIVs prepared by IEM on A/Leningrad/134/17/57 (H2N2) and
B/USSR/60/69 backbone, which were transferred to WHO.
Vaccine strain designation
(LAIV candidate)
Wild-type parental strain Influenza
seasona
B/56/Brisbane/60/2008 B/Brisbane/60/2008 (Victoria
lineage)
2009–2010
2010–2011
2011–2012
2016–2017
A/17/California/2009/38
(H1N1)pdm09b
A/California/07/2009
(H1N1pdm)
2009–2010
2010–2011
2011–2012
2012–2013
2013–2014
2014–2015
A/17/Perth/2009/87 (H3N2) A/Perth/16/2009 (H3N2) 2010–2011
2011–2012
B/60/Wisconsin/2010/125 B/Wisconsin/1/2010
(Yamagata lineage)
2012–2013
A/17/Victoria/2011/89
(H3N2)
A/Victoria/361/2011 (H3N2) 2012–2013
2013–2014
A/17/Texas/2012/30 (H3N2) A/Texas/50/2012 (H3N2) 2013–2014
2014–2015
B/60/Massachusetts/2012/10 B/Massachusetts/2/2012
(Yamagata lineage)
2013–2014
2014–2015
B/60/Phuket/2013/26 B/Phuket/3073/2013
(Yamagata lineage)
2015–2016
A/17/Bolivia/2013/6585
(H1N1)pdm09
A/Bolivia/559/2013 (H1N1)
pdm2009
2015–2015
A/17/Hong Kong/2014/8296
(H3N2)
A/Hong Kong/4801/2014
(H3N2)
2016–2017
IEM – Institute of Experimental Medicine; LAIV – live attenuated influenza vaccine;
WHO – World Health Organization.
a Northern hemisphere influenza season.
b Vaccine is registered in Russia.
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has likewise been shown to provide superior protective efficacy in
children, compared to IIV, through randomized controlled trials.
Some recent studies have however suggested that since 2011 there
has been a reduction in the comparative efficacy of the Ann-Arbor
based LAIV compared to IIV. The cause is still unknown however
efforts to understand this sudden loss of efficacy are focusing on
the role of the A/California H1N1 component as well as the inclu-
sion of a second B-strain, and it is expected that this issue will
be successfully addressed.2. Transfer of Russian LAIV technology
BioDiem Ltd. (Melbourne, Australia), holding the rights for use
of the Russian MDVs, licensed Russian LAIV technology to WHOTable 2
List of potentially pandemic LAIVs prepared by IEM on A/Leningrad/134/17/57 (H2N2) ba
Vaccine strain designation (LAIV candidate) Wild-type strain
A/17/turkey/Turkey/05/133 (H5N2) NIBRG–23 (H5N1), clade 2
A/17/Vietnam/04/65107 (H5N2) IDCDC–RG1 (H5N1), clade
A/17/California/66/395 (H2N2) A/California/1/66 (H2N2)
A/17/Anhui/2013/61 (H7N9) A/Anhui/1/2013 (H7N9)
A/17/mallard/Netherlands/00/95 (H7N3) A/mallard/Netherlands/12/
IEM – Institute of Experimental Medicine; LAIV – live attenuated influenza vaccine; WH[4]. The agreement with BioDiem permitted WHO to grant
sub-licenses to vaccine manufacturers in the newly industrialized
countries (NICs) and developing countries within the framework
of the WHO influenza vaccine technology transfer project. Since
2009, WHO has signed agreements with the Changchun BCHT
Biotechnology Co., Ltd. (BCHT, Changchun, Jilin, China), the Serum
Institute of India Pvt. Ltd. (SIIPL, Pune, India) and the Government
Pharmaceutical Organization (GPO, Bangkok, Thailand) for the
development, manufacture, use and sale of the egg-based LAIV
using Russian MDVs.
At the same time, the Institute of Experimental Medicine (IEM),
Saint Petersburg, Russia – the sole developer of reassortant strains
for Russian LAIV – signed an agreement with WHO. Under this
agreement, there were two main areas of work: development of
seasonal LAIV candidates according to biannual WHO recommen-
dations for influenza vaccine compositions, and Development of
LAIV candidates against potentially pandemic influenza viruses.
During the period 2009–2015, IEM developed and transferred to
WHO nine seed-LAIVs for seasonal vaccines and one H1N1 pan-
demic seed-LAIV for further distribution to manufacturers (Tables
1 and 2). All of these LAIV candidates were accompanied by strain
certificates drawn up in accordance with international standards,
which included detailed descriptions of the seed-LAIV generation
and the quality-control attributes; that is, antigenicity and identity
tests, phenotypic and propagation characteristics, genetic stability
data, full genome sequencing, sterility control and safety preclini-
cal testing in laboratory animals.
In 2012, the increased international demand for the Russian
LAIV prompted the establishment of an additional (back-up) labo-
ratory facility at the Centers for Disease Control and Prevention
(CDC), Atlanta, Georgia, United States of America (USA) for parallel
preparation of the LAIV candidates based on Russian MDVs for
international use. The organizations responsible for this were
WHO, the Biomedical Advanced Research and Development
Authority (BARDA), USA, and IEM. This decision made it possible
to reduce the unpredictable risks associated with the production
of LAIV candidates in one laboratory and in one country alone.
The back-up laboratory has been working successfully [5–8] and
a number of reassortants have been used to produce the LAIV in
India and China (Table 4).3. Creation of a modern high-tech pathogenic agent’s
laboratory facility and development of potentially pandemic
LAIV candidates
To meet the demand for high-quality LAIV seed viruses for fur-
ther distribution between dedicated manufacturers, it was neces-
sary to reconstruct and build a new state-of-the-art facility at
IEM to work with pathogens of biosafety level BSL-2 and BSL-3
groups, in compliance with all international biosafety standards.
For this purpose WHO, in collaboration with BARDA, allocated all
necessary funds, and the construction was completed in 2014.
Since then, the facility has been fully operational and has been cer-
tified by the Russian Ministry of Health. This laboratory occupies ackbone, which were transferred to WHO.
The stage of the study Ref.
.2 Phase I clinical trial completed [7,19]
1 Preclinical trials completed [7]
Phase I clinical trial completed [8,18]
Phase I clinical trial completed [9,20]
2000 (H7N3) Phase I clinical trial completed [10,17]
O – World Health Organization.
Table 3
Preclinical evaluation of pandemic LAIV candidates in animal models.
Pandemic/potentially
pandemic LAIV candidate
Animal
model
Main findings Ref.
A/17/California/2009/38
(H1N1)pdm09
Ferrets Single immunization induced high serum HAI antibody titers and the animals were protected against
intratracheal wild-type pH1N1 virus challenge: virus replication in URT and LRT was reduced and no disease
signs or severe broncho-interstitial pneumonia were observed in any of the vaccinated ferrets
[11]
A/17/turkey/Turkey/05/133
(H5N2)
Ferrets Two doses elicited high levels of homologous and heterologous HAI antibody titers to clades 1, 2.1 and 2.2 H5N1
HPAI viruses. All vaccinated animals were fully protected against lethal challenge with homologous HPAI virus:
no virus was detected in LRT, and the titers were significantly reduced in URT
[7]
VN1203/H5N1 rg Mice Two doses induced high titers of HAI antibodies which cross-reacted with clade 2.2 HPAI virus; animals were
fully protected against lethal challenge with homologous and heterologous HPAI viruses
[12]
VN1203/H5N1 rg Ferrets Two doses elicited strong cross-reactive immune response; animals were protected from homologous and
heterologous challenge with clade 1 and clade 2.2 HPAI viruses; a superior cross-protection of LAIV over
inactivated vaccine was demonstrated in this challenge study
[13]
A/17/mallard/Netherlands/00/
95 (H7N3)
Mice Double immunization with high-dose vaccine elicited modest HAI antibody titers; nevertheless, the animals
were protected against wild-type H7N3 virus replication in URT and LRT
[14]
A/17/mallard/Netherlands/00/
95 (H7N3)
Ferrets The vaccine virus replication was not detected in animal respiratory tissues; however, high levels of HAI
antibodies were induced which cross-reacted with heterologous H7N9 virus; animals were protected from
H7N3 and H7N9 wild-type viruses by reducing virus replication in URT and LRT; passively immunized ferrets
were protected against lethal challenge with H7N9 virus, reduced weight loss and viral titers in URT
[14,15]
A/17/California/66/395
(H2N2)
Ferrets Single immunization elicited very high titers of homologous and heterologous HAI, MN and NAI antibodies;
protected animals from homologous and heterologous challenge by reducing virus titers in URT and LRT and
nasal turbinate tissue damage
[8]
A/17/Anhui/2013/61 (H7N9) Ferrets Both single and two-dose immunizations were highly immunogenic, prevented H7N9 wild-type virus
replication in respiratory tissues and protected animals against severe bronchopneumonia
[9]
HAI – hemagglutination inhibition; HPAI – highly pathogenic avian influenza virus; LAIV – live attenuated influenza vaccine; LRT – lower respiratory tract;
MN – microneutralization; NAI – neuraminidase inhibition; URT – upper respiratory tract.
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facilities covering an area of over 1000 m2. Additional financing
for the purchase of the equipment was provided by the Program
for Appropriate Technologies in Health (PATH), Seattle, Washing-
ton, USA.
Including the LAIV into the WHO Global action plan for influ-
enza vaccines required the generation of a panel of LAIV candidates
against potentially pandemic H5N1, H2N2, H7N9 and H7N3 influ-
enza viruses. According to collaborative agreements between IEM,
PATH and WHO, the following potentially pandemic LAIV candi-
dates were developed: A/17/turkey/Turkey/05/133 (H5N2) [9],
A/17/Vietnam/04/65107 (H5N2) [9], A/17/California/66/395
(H2N2) [10], A/17/Anhui/2013/61 (H7N9) [11], A/17/mallard/Neth
erlands/00/95 (H7N3) [12] (Table 2).
3.1. Preclinical testing
Studies on the safety, immunogenicity and protective efficacy of
these potentially pandemic LAIV candidates in ferrets were con-
ducted in collaboration with experts from the Centre for Infectious
Disease Control (Bilthoven, Netherlands), University of Pittsburgh
(Pittsburgh, Pennsylvania, USA), Southeast Poultry Research Labo-
ratory (Athens, Georgia, USA), CDC (Atlanta, Georgia, USA) and
ViroClinics Biosciences (Rotterdam, Netherlands) [9–11,13–16]. It
was demonstrated that immunization with the potentially pan-
demic LAIV candidates induced a strong immune response, and
the ferrets were protected against homologous and heterologous
wild-type virus challenge. Replication of challenge viruses in the
upper and lower respiratory tracts of immunized animals was sig-
nificantly reduced compared to the controls, and no signs of dis-
ease were observed in any of the vaccinated animals (Table 3).
3.2. Clinical trials
Phase I clinical trials of the potentially pandemic LAIV candi-
dates of H5N2, H7N3, H2N2 and H7N9 subtypes were conducted
in clinics of the Research Institute of Influenza (Saint Petersburg,
Russia). All trials were randomized, double-blinded, placebo-
controlled studies in healthy adults. In order to minimize thepotential for vaccine virus to release into the environment vaccina-
tions took place in an inpatient isolation unit; subjects were tested
for influenza virus in nasal swabs prior to vaccination; presence of
vaccine virus in nasal swabs was assessed daily; subjects were to
be kept in the isolation unit until shedding was no longer detected;
an independent Safety Monitoring Committee reviewed the safety
and shedding data.
These LAIVs were found to be safe, well tolerated and immuno-
genic in human adult volunteers [4,17–20]. Catarrhal symptoms,
such as hyperemia and sore throat, were the most frequently
reported adverse events with the pandemic LAIVs. The frequency
of reporting sore throat following LAIV administration ranged from
11% (for H2N2 LAIV) to 27% (for H7N3 LAIV). The vaccine viruses
were recovered from the nasal or throat swabs of vaccinees by
virus culture in embryonated eggs, with most of the subjects scor-
ing positive for virus shedding only on the first day after vaccina-
tion. No vaccine virus or viral RNA was detected in any of the
placebo recipients after either the first or the second vaccine dose
for any of the five LAIVs reported here. Importantly, the lack of vac-
cine virus transmission to placebo recipients was observed despite
co-housing all subjects (vaccine and placebo recipients) in the
same isolation facility. This finding may support the lack of vaccine
transmissibility of LAIVs.
Immunization with potentially pandemic LAIVs induced high
levels of hemagglutination inhibition (HAI) and local secretory
antibodies, as well as long-lasting B-cell immunological memory
against antigenically related influenza virus. Taking into account
all the assays conducted (HAI, microneutralization, enzyme-
linked immunosorbent assay [ELISA] and cytokine flow cytometry),
an immune response was observed in 70.2% of H1N1pdm09-LAIV
recipients, 96.6% of H5N2-LAIV recipients, 86.2% of H7N3-LAIV
recipients, 92.6% of H2N2-LAIV recipients and 93.1% of
H7N9-LAIV recipients. In contrast, none of the placebo recipients
exhibited any response (Fig. 1).4. Progress of development of LAIV in the NICs
The declaration of 2009 H1N1 influenza pandemic prompted
SIIPL and GPO to start immediate manufacturing of pandemic LAIV.
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cessfully produced H1N1pdm09 LAIV, conducted preclinical and
clinical trials of this vaccine, and registered it in 2011 [21]. Since
the registration of H1N1pdm09 LAIV, intensive studies of another
pre-pandemic LAIV candidate – H5N2 – have been carried out at
GPO. These studies are progressing well and are nearing comple-
tion. Thus, Thailand is well on the way to having LAIVs ready to
respond to a pandemic.
In 2011, the BCHT signed an agreement with WHO, and since
then the company has built a manufacturing plant and adopted
the LAIV production technology. BCHT is currently conducting
Phase I clinical trials of seasonal LAIV.
The LAIV promotion in India was the most successful. SIIPL
developed a lyophilized monovalent H1N1pdm09 LAIV that was
reconstituted with water for inhalation; it showed satisfactory sta-
bility of 9 months. Preclinical studies in ferrets showed remarkable
protection after challenge with wild-type virus, with one dose of
the vaccine [13].
Clinical experience with the monovalent H1N1pdm09 LAIV
showed a good safety profile of the vaccine in all age groups,
including children aged over 3 years. The immune response was
in line with the other LAIVs. The vaccine was developed, licensed
and commercialized within 12 months [22]. Post-marketing
surveillance and the periodic safety update reports further estab-
lished the safety of the vaccine [23]. A case-control study alsoFig. 1. Antibody and cell-mediated immune responses to pandemic LAIVs in clinical tria
vaccine. Cal/09 H1N1pdm: A/17/California/2009/38 (H1N1); t/Turkey H5N2: A/17/tur
(H7N3) LAIV; HAI – hemagglutination inhibition; MN – microneutralization; CMI – cell-m
H1N1pdm LAIV.  Only antibody immune responses are included in calculations becausdemonstrated high effectiveness of the vaccine during the epi-
demic [24].
One of the major issues related to pandemic preparedness is the
availability of a pre-existing manufacturing setup that can be
geared up for large-scale vaccine production in the face of a pan-
demic. This would be possible only if continual manufacturing of
the influenza vaccine for the annual vaccination was maintained.
Understanding this need, SIIPL ventured into development of a sea-
sonal trivalent LAIV, prepared using the same manufacturing pro-
cess and stabilizer as the monovalent H1N1pdm09LAIV, and with
a stability of 9 months.
The trivalent LAIV was tested in a ferret challenge study, and
established protection from all three strains. The clinical trials
involved safety assessment and immunogenicity testing in individ-
uals aged over 2 years, which both demonstrated acceptable
results. The vaccine was licensed by the Indian authorities in Jan-
uary 2014 and is prequalified by WHO.
Since the development of LAIV at SIIPL five different composi-
tions recommended for the northern and southern hemisphere
have been manufactured and used successfully (Table 4).
Two clinical trials to assess efficacy in children aged 2–5 years
were conducted by PATH in Bangladesh and Senegal [25]. The vac-
cine was found to be efficacious in this age group in Bangladesh.
Surprisingly, the Senegal study indicated no protection in the same
age group using the same lot of the vaccine. These contrastingls. (A) Immune responses after dose 1; (B) Immune responses after two doses of the
key/Turkey/05/133 (H5N2) LAIV; mal/NL H7N3: A/17/mallard/Netherlands/00/84
ediated immune response. y MN and serum IgA tests were not performed for Cal/09
e only a small proportion of subjects was tested for CMI.
Table 4
LAIV candidates recommended by WHO for the northern and southern hemisphere, used by SIIPL for manufacturing LAIV in 2011–2016.
Influenza season Type/subtype Recommended strain Vaccine strain designation Prepared by
2011 SH H1N1 A/California/07/2009 A/17/California/2009/38 IEM
2011–2012 NH H3N2 A/Perth/16/2009 A/17/Perth/09/87 IEM
2012 SH B B/Brisbane/60/2008 B/56/Brisbane/60/08 Nobilon
2012–2013 NH H1N1 A/California/07/2009 A/17/California/2009/38 IEM
2013 SH H3N2 A/Victoria/361/2011 A/17/Victoria/2011/89 IEM
B B/Wisconsin/1/2010 B/60/Wisconsin/1/2010 IEM
2013–2014 NH H1N1 A/California/07/2009 A/17/California/2009/38 IEM
2014 SH H3N2 A/Texas/50/2012 A/17/Texas/2012/30 IEM
2014–15 NH B B/Massachusetts/2/2012 B/60/Massachusetts/2012/10 IEM
2015 SH H1N1 A/California/07/2009 A/17/California/2009/38 IEM
2015–16 NH H3N2 A/Switzerland/9715293/2013 A/Switzerland/9715293/2013CDC–LV10A CDC
B B/Phuket/3073/2013 B/60/Phuket/2013/26 IEM
2016 SH H1N1 A/California/07/2009 A/17/California/2009/38 IEM
H3N2 A/Hong Kong/4801/2014 A/17/Hong Kong/2014/8296 IEM
B B/Brisbane/60/2008 B/Texas/02/2013–CDC–LV8B CDC
CDC – Centers for Disease Control and Prevention; IEM – Institute of Experimental Medicine; LAIV – live attenuated influenza vaccine; NH – northern hemisphere influenza
season; SH – southern hemisphere influenza season; SIIPL – Serum Institute of India Pvt. Ltd.; WHO – World Health Organization.
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antigenic make up of the circulating strains, population behavior
and so on.
One more clinical trial of seasonal LAIV by the CDC is ongoing in
children at Ballabgarh, Haryana, India (see vaccine composition in
Table 4). This trial is in its second year of immunization and is
expected to be completed by mid 2017. Furthermore, an age de-
escalation study aimed at immunizing children aged 6–24 months
is under consideration.
Some manufacturers are now producing quadrivalent vacci-
nes to include both lineages of influenza type B which are
co-circulating. Twice per year WHO recommends the composi-
tion of strains for both trivalent and quadrivalent vaccines. SIIPL
developed a good manufacturing practice (GMP)-grade egg-
based quadrivalent preparation of LAIV that was tested in the
ferret model for immunogenicity and efficacy.
Further efforts are being made to develop rapid up scaling
capacity for the vaccine production during a pandemic. To make
the delivery user-friendly, the quadrivalent vaccine has been
developed as a ready-to-use liquid vaccine and the nasal delivery
devices have been upgraded.
Considering the unpredictable demand for influenza vaccines in
India, and worldwide in general, pre-ordering for large quantity of
eggs is a major challenge. An obvious solution to this problem is
the development of a tissue culture-based LAIV. A well-
characterized Madin-Darby canine kidney (MDCK) cell bank has
been prepared by SIIPL and experimental batches have been pre-
pared. Further work to develop GMP LAIV lots is underway.
The SIIPL is aiming towards a MDCK-based quadrivalent liquid
LAIV that will have an ideal influenza vaccine profile including
safety, efficacy, stability and ease of administration, as well as high
capacity to rapidly increase the production.5. Summary
1. Studies of LAIV in developing countries are based on over
40 years of monitoring the implementation of LAIV in
Russia. A number of seasonal LAIV candidates using the
A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 backbone
were developed by IEM and the newly formed back-up labora-
tory at the CDC. All these vaccine strains were supplied to three
countries: China (BCHT), India (SIIPL) and Thailand (GPO) for
the production of LAIV and the preparation for vaccine
registration.2. A modern high-tech BSL-2 and BSL-3 facility was built in IEM
with financial support from BARDA and WHO. Since 2009, a
number of LAIV candidates against the most potentially pan-
demic influenza viruses subtypes – namely H1N1, H5N2,
H7N3, H2N2 and H7N9 – have been prepared. Safety, immuno-
genicity and efficacy of these candidates in the animal models
were demonstrated in collaboration with the Centre for Infec-
tious Disease Control (Netherlands), University of Pittsburgh
(USA), Southeast Poultry Research Laboratory (USA), CDC
(USA) and ViroClinics Biosciences (Netherlands).
3. All the above-mentioned pandemic and pre-pandemic LAIV
candidates have been included in the Phase I clinical trials in
adult volunteers, in collaboration with PATH, the Research
Institute of Influenza (Saint Petersburg, Russia) and Microgen
(Moscow, Russia). Vaccines demonstrated a good safety profile
and were well tolerated. The two-dose immunization schedule
resulted in measurable serum and local antibody production,
and generation of CD4+ and CD8+ memory T cells. The results
of the clinical trials were published [4,17–20].
4. In 2009, GPO produced H1N1pdm LAIV, conducted preclinical
and clinical trials, and registered the vaccine in Thailand. The
work for preparation and registration of H5N2 pre-pandemic
vaccine is in progress.
5. BCHT completed the construction of the manufacturing plant
and produced vaccine clinical lots. Clinical trials began in March
2016. In 2019, BCHT intends to finalize registration of LAIV and
begin its use for influenza prevention.
6. SIIPL registered the monovalent pandemic H1N1 LAIV in 2010
and the trivalent seasonal LAIVs in 2014 in India. Both the vac-
cines have been prequalified by WHO. Currently, Indian LAIV is
used for the prophylaxis of seasonal influenza. Today, SIIPL is
conducting research on the improvement of vaccine prepara-
tion and expansion of the age groups, and is aiming to produce
MDCK-derived liquid LAIV.
7. The incorporation of production of LAIVs based on
A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 donors of
attenuation developed in Russia into the WHO global pandemic
influenza action plan has led to significant progress on the
development and the promotion of the LAIV for influenza
prophylaxis in countries with large populations.
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